Connor J Kinslow1, Andrew L A Garton2, Ali I Rae3, Logan P Marcus4, Christopher M Adams5, Guy M McKhann6,7, Michael B Sisti6,7, E Sander Connolly6,7, Jeffrey N Bruce6,7, Alfred I Neugut7,8, Adam M Sonabend9, Peter Canoll7,10, Simon K Cheng1,7, Tony J C Wang11,12. 1. Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 622 West 168th Street, BNH B011, New York, NY, 10032, USA. 2. Department of Neurological Surgery, NewYork-Presbyterian Hospital / Weill Cornell Medical Center, 525 E 68th Street, New York, NY, 10065, USA. 3. Department of Neurological Surgery, Oregon Health & Sciences University, 3181 SW Sam Jackson Pkwy, Portland, OR, 97239, USA. 4. Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA. 5. Division of Biostatistics, New York State Psychiatric Institute, Columbia University Irving Medical Center, 722 West 168th Street, New York, NY, 10032, USA. 6. Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 710 West 168th Street, New York, NY, 10032, USA. 7. Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 1130 St Nicholas Ave, New York, NY, 10032, USA. 8. Department of Epidemiology, Mailman School of Public Health, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 722 West 168th St, New York, NY, 10032, USA. 9. Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 2210, Chicago, IL, 60611, USA. 10. Departments of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 1130 St. Nicholas Ave Rm.1001, New York, NY, 10032, USA. 11. Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 622 West 168th Street, BNH B011, New York, NY, 10032, USA. tjw2117@cumc.columbia.edu. 12. Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, 1130 St Nicholas Ave, New York, NY, 10032, USA. tjw2117@cumc.columbia.edu.
Abstract
BACKGROUND: National guidelines recommend maximal safe resection of low-grade and high-grade oligodendrogliomas. However, there is no level 1 evidence to support these guidelines, and recent retrospective studies on the topic have yielded mixed results. OBJECTIVE: To assess the association between extent of resection (EOR) and survival for oligodendrogliomas in the general U.S. METHODS: Cases diagnosed between 2004 and 2013 were selected from the Surveillance, Epidemiology, and End-Results (SEER) Program and retrospectively analyzed for treatment, prognostic factors, and survival times. Cases that did not undergo tumor de-bulking surgery (e.g. no surgery or biopsy alone) were compared to subtotal resection (resection) and gross-total resection (GTR). The primary end-points were overall survival (OS) and cause-specific survival (CSS). An external validation cohort with 1p/19q-codeleted tumors was creating using the TCGA and GSE16011 datasets. RESULTS: 3135 Cases were included in the final analysis. The 75% survival time (75ST) and 5-year survival rates were 47 months and 70.8%, respectively. Subtotal resection (STR, 75ST = 50 months) and GTR (75ST = 61 months) were associated with improved survival times compared to cases that did not undergo surgical debulking (75ST = 20 months, P < 0.001 for both), with reduced hazard ratios (HRs) after controlling for other factors (HR 0.81 [0.68-0.97] and HR 0.65 [0.54-0.79], respectively). GTR was associated with improved OS in both low-grade and anaplastic oligodendroglioma subgroups (HR 0.74 [0.58-0.95], HR 0.60 [0.44-0.82], respectively) while STR fell short of significance in the subgroup analysis. All findings were corroborated by multivariable analysis of CSS and externally validated in a cohort of patients with 1p19q-codeleted tumors. CONCLUSION: Greater EOR is associated with improved survival in oligodendrogliomas. Our findings in this U.S. population-based cohort support national guidelines.
BACKGROUND: National guidelines recommend maximal safe resection of low-grade and high-grade oligodendrogliomas. However, there is no level 1 evidence to support these guidelines, and recent retrospective studies on the topic have yielded mixed results. OBJECTIVE: To assess the association between extent of resection (EOR) and survival for oligodendrogliomas in the general U.S. METHODS: Cases diagnosed between 2004 and 2013 were selected from the Surveillance, Epidemiology, and End-Results (SEER) Program and retrospectively analyzed for treatment, prognostic factors, and survival times. Cases that did not undergo tumor de-bulking surgery (e.g. no surgery or biopsy alone) were compared to subtotal resection (resection) and gross-total resection (GTR). The primary end-points were overall survival (OS) and cause-specific survival (CSS). An external validation cohort with 1p/19q-codeleted tumors was creating using the TCGA and GSE16011 datasets. RESULTS: 3135 Cases were included in the final analysis. The 75% survival time (75ST) and 5-year survival rates were 47 months and 70.8%, respectively. Subtotal resection (STR, 75ST = 50 months) and GTR (75ST = 61 months) were associated with improved survival times compared to cases that did not undergo surgical debulking (75ST = 20 months, P < 0.001 for both), with reduced hazard ratios (HRs) after controlling for other factors (HR 0.81 [0.68-0.97] and HR 0.65 [0.54-0.79], respectively). GTR was associated with improved OS in both low-grade and anaplastic oligodendroglioma subgroups (HR 0.74 [0.58-0.95], HR 0.60 [0.44-0.82], respectively) while STR fell short of significance in the subgroup analysis. All findings were corroborated by multivariable analysis of CSS and externally validated in a cohort of patients with 1p19q-codeleted tumors. CONCLUSION: Greater EOR is associated with improved survival in oligodendrogliomas. Our findings in this U.S. population-based cohort support national guidelines.
Entities:
Keywords:
Extent of resection; Gross-total resection; Oligodendroglioma; Surgery
Authors: B Jeremic; Y Shibamoto; D Gruijicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic Journal: J Neurooncol Date: 1999-06 Impact factor: 4.130
Authors: Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: C Lebrun; D Fontaine; A Ramaioli; F Vandenbos; S Chanalet; M Lonjon; J F Michiels; V Bourg; P Paquis; M Chatel; M Frenay Journal: Neurology Date: 2004-05-25 Impact factor: 9.910
Authors: Gregory S Cooper; Beth Virnig; Carrie N Klabunde; Nicola Schussler; Jean Freeman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Michael S May; Connor J Kinslow; Christopher Adams; Anjali Saqi; Catherine A Shu; Kunal R Chaudhary; Tony J C Wang; Simon K Cheng Journal: Transl Lung Cancer Res Date: 2021-01
Authors: Gabrielle Metz; Dasantha Jayamanne; Helen Wheeler; Matthew Wong; Raymond Cook; Nicholas Little; Jonathon Parkinson; Marina Kastelan; Chris Brown; Michael Back Journal: BMC Neurol Date: 2022-01-13 Impact factor: 2.474
Authors: Nancy Ann Oberheim Bush; Jacob S Young; Yalan Zhang; Cecilia L Dalle Ore; Annette M Molinaro; Jennie Taylor; Jennifer Clarke; Michael Prados; Steve E Braunstein; David R Raleigh; Susan M Chang; Mitchel S Berger; Nicholas A Butowski Journal: J Neurooncol Date: 2021-06-14 Impact factor: 4.130
Authors: Dieter H Heiland; Robin Ohle; Debora Cipriani; Pamela Franco; Daniel Delev; Simon P Behriger; Elias Kellner; Gergana Petrova; Nicolas Neidert; Irina Mader; Mateo Fariña Nuñez; Horst Urbach; Roman Sankowski; Jürgen Beck; Oliver Schnell Journal: BMC Cancer Date: 2020-08-27 Impact factor: 4.638